Pazopanib, a new therapy for metastatic soft tissue sarcoma

Bibliography

• Bovee JV, Hogendoorn PC. Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch 2010;456:193-9
   PubMed Web of Science ®Google Scholar
• Verweij J, Baker LH. Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer 2010;46:863-8
   PubMed Web of Science ®Google Scholar
• Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii92-9
   PubMedGoogle Scholar
• Verweij J, Casali PG, Zalcberg J, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Von Mehren M, Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma of leiomyosarcoma after failure of prior anthracylcines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27:4188-96
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD, Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32
   PubMed Web of Science ®Google Scholar
• Potti A, Ganti AK, Tendulkar K, Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role in leiomyosarcoma. J Cancer Res Clin Oncol 2004;130:52-6
   PubMed Web of Science ®Google Scholar
• Chao C, Al-Saleem T, Brooks JJ, Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlated with grade. Ann Surg Oncol 2001;8:260-7
   PubMed Web of Science ®Google Scholar
• Pakos EE, Goussia AC, Tsekeris PG, Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 25:3591-6.2005
   PubMed Web of Science ®Google Scholar
• Yudoh K, Kanamori M, Ohmori K, Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001;84(12):1610-15
   PubMed Web of Science ®Google Scholar
• Graeven U, Andre N, Achilles E, Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol 1999;125:577-81
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Mostyn-Jones A, Koban MU, Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 2004;91:242-7
   PubMed Web of Science ®Google Scholar
• Yoon SS, Segal NH, Olshen AB, Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft-tissue sarcoma. Ann Oncol 2004;15:1261-6
   PubMed Web of Science ®Google Scholar
• Yoon SS, Segal NH, Park PJ, Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Oncol 2006;135:282-90
   Google Scholar
• Wang J, Coltrera MD, Gown AM, Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor-B chain expression: an immunohistochemical and in situ hybridization assay. Cancer Res 1994;560-4
   PubMed Web of Science ®Google Scholar
• Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 2010;15(6):539-47
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, Pharmacokinetic-pharmacodynamic correlation from mouse to human with Pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and angiogenic activity. Mol Cancer Ther 2007;6:2012-21
   PubMed Web of Science ®Google Scholar
• van Geel RMJM, Beijen JH, Schellens JHM. Concise drug review: pazopanib and axitinib. Oncologist 2012;17:1081-9
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Dowlati A, Saini S, Phase I trial of Pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-7
   PubMed Web of Science ®Google Scholar
• Heath EI, Chiorean EG, Sweeney CJ, A phase I study of the pharmacokinetic and safety profile of oral Pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 2010;88:818-23
   PubMed Web of Science ®Google Scholar
• de Jonge MJ, Hamberg P, Verweij J, Phase I and pharmacokinetic study of Pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Monk BL, Mas Lopez L, Zarba JJ, Phase II open-label study of pazopanib or lapatinib monotherapy compared with Pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562-9
   PubMed Web of Science ®Google Scholar
• Tan AR, Dowlati A, Jones SF, Phase I study of Pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010;15:1253-61
   PubMed Web of Science ®Google Scholar
• Hamberg P, Boers-Sonderen M, Loos WJ, Phase I and pharmacokinetic study of Pazopanib in combination with two schedules of ifosfamide in patients with advanced solid tumors. J Clin Oncol 2012;30(Suppl):abstract 2593
   Google Scholar
• Park MS, Patel SR, Ludwig JA, Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 2011;117:4939-47
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Judson I, Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2011;38:543-9
   Google Scholar
• Verweij J. Soft tissue sarcoma trials: one size no longer fits all. J Clin Oncol 2009;27:3085-7
   PubMed Web of Science ®Google Scholar
• Baker LH, Rowinsky EK, Mendelson D, Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008;26:5583-8
   PubMed Web of Science ®Google Scholar
• George S, Merriam P, Maki RG, Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154-60
   PubMed Web of Science ®Google Scholar
• Maki RG, D'Adamo DR, Keohan ML, Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133-40
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol 2009;27:3126-32
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Gorlia T, Lamers C, Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue: an EORTC-STBSG study. Br J Cancer 2012;107:639-45
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
   PubMed Web of Science ®Google Scholar